MSC-derived exosomes for hemorrhagic stroke: preclinical evidence and translational challenges
Salinas I., Vela L., Santos S., Moncayo A., Moreno K., Guaillas A.
Animal Study on Stroke Research, Neuroinflammation, published in Front Neurol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Front Neurol (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42136804
- PMCID
- PMC13167550
- DOI
- 10.3389/fneur.2026.1711050
Abstract (original English)
Hemorrhagic stroke, caused by bleeding into the brain parenchyma or subarachnoid space, accounts for 10-20% of cerebrovascular events worldwide. It is classified as intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH). Despite distinct etiologies, both forms initiate a shared injury cascade marked by metabolic failure, mitochondrial dysfunction, oxidative stress, cytotoxic edema, and progressive neuronal loss. Current guidelines prioritize time-sensitive, neuroprotective measures aimed at acute stabilization and complication prevention. However, these interventions remain largely supportive and fail to directly address the sustained secondary injury processes that underlie long-term neurological disability. In this Perspective, we focus on mesenchymal stem/stromal cell (MSCs)-derived exosomes as a promising cell-free therapeutic strategy with distinct advantages over MSC-based therapies. We first provide an overview of the key mechanisms of neuronal injury in hemorrhagic stroke, distinguishing early brain injury from delayed, secondary damage. We then define exosomes within the broader extracellular vesicle landscape and explain why MSC-derived exosomes are emphasized as principal mediators of MSC paracrine effects. Finally, we synthesize preclinical evidence showing that exosomes can attenuate neuroinflammation, limit apoptosis, and promote angiogenesis and neurogen
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Stem cell therapy for ischemic stroke: neuroimaging approaches and evidence from a systematic review
Meta-analysis on Stroke Research, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev - Level AMeta-analysisEurope PMC
Efficacy and Potential Mechanisms of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Ischemic Stroke in Animal Models: A Meta-Analysis
Meta-analysis on Stroke Research, published in CNS Neurosci Ther (2025) — summary generated from the PubMed abstract.
- 2025
CNS Neurosci Ther5 citations - Level AMeta-analysisPubMed
The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs.
Meta-analysis with a reported sample of 1184 on Cardiovascular Disease, Stroke Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
- n = 1184
Stem Cell Res Ther2 citations - Level ASystematic ReviewEurope PMC
In vitro and In vivo Studies on Mesenchymal Stem Cells for Ischemic Stroke Therapy: A Scoping Review of The Therapeutic Effect
Systematic Review on Stroke Research, published in Stem Cells Cloning (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cells Cloning